Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Baxter Int'l Q1 Profit Tops View; Backs 2012 Outlook

RELATED NEWS
Trade BAX now with 

Healthcare company Baxter International, Inc. (BAX: Quote) reported Thursday a profit for the first quarter that increased 3 percent from last year, helped by sales growth. Adjusted earnings per share and quarterly revenues topped analysts' expectations.

Further, the company issued earnings and revenue growth forecast for the second quarter, in line with Street view, and backed its guidance for the full-year 2012.

"Baxter has entered 2012 with strong momentum and confidence in our continued success. Our sustained focus on innovation and growth opportunities enables us to respond effectively to an evolving macroeconomic environment, while strengthening our market leadership and expanding access to care, achieving the highest standards of quality and safety, and creating enhanced value for Baxter, our shareholders, and patients worldwide," Chairman and CEO Robert Parkinson, Jr. said in a statement.

The Deerfield, Illinois-based drug maker posted net income of $588 million or $1.04 per share for the first quarter, higher than $570 million or $0.98 per share in the prior-year quarter.

Excluding items, adjusted net income for the quarter was $569 million or $1.01 per share, compared to $570 million or $0.98 per share in the year-ago quarter.

On average, 16 analysts polled by Thomson Reuters expected the company to report earnings of $1.00 per share for the first quarter. Analysts' estimates typically exclude special items.

Worldwide sales for the quarter increased 3 percent to $3.39 billion from $3.28 billion in the same quarter last year, and surpassed fourteen Wall Street analysts' consensus revenue estimate of $3.30 billion. Excluding the impact of foreign exchange, sales grew 4 percent.

Sales within the U.S. increased 3 percent to $1.47 billion and international sales amounted to $1.92 billion, a growth of 3 percent or 5 percent in constant currency, over the same period last year.

Baxter's bioScience business generated sales of $1.46 billion, up 4 percent or 5 percent in constant currency, over last year, and medical products sales were up 3 percent to $1.93 billion.

Gross profit for the quarter was $1.71 billion, up 2 percent from $1.68 billion in the year-ago quarter, while gross margin percentage edged down 40 basis points to 50.6 percent from last year.

Looking ahead to the second quarter, Baxter expects adjusted earnings in a range of $1.10 to $1.12 per share on a projected quarterly sales growth of 3 to 4 percent from last year. Analysts expect the company to report earnings of $1.12 per share on quarterly revenues of $3.55 billion.

For fiscal 2012, the company continues to anticipate adjusted earnings in a range of $4.49 to $4.57 per share on expected annual sales growth of 4 to 5 percent from last year. Street is currently looking for full-year 2012 earnings of $4.53 per share on annual revenues of $14.20 billion.

In Thursday's regular trading session, BAX is currently trading at $54.40, up $0.01 or 0.02% on a volume of 0.38 million shares.

Register
To receive FREE breaking news email alerts for Baxter International Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Kraton Performance Polymers, Inc. (KRA), Wednesday reported second-quarter net income of $11.1 million or $0.33 per share, up from $3.8 million or $0.12 per share last year. Adjusted earnings improved to $0.46 per share from $0.15 per share last year. Revenues for the quarter dropped to $323.8... Organic grocer Whole Foods Market, Inc. said Wednesday after the markets closed that its third quarter profit rose 6.3% from last year, as same-store sales increased 3.9%. The company's quarterly earnings per share also came in above analysts' expectations, but its quarterly sales fell shy of analyst' forecast. Micro-blogging site Twitter Inc said Tuesday after the markets closed that its second quarter loss widened from last year, hurt mainly by stock-based compensation expense, even as revenue more than doubled thanks to growth in advertising. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.